Big gain for Deciphera as GIST readout portends face-off with Blueprint

New Phase III data in GIST burnished Deciphera's case for an upcoming regulatory submission, pushing the company's market cap to about $1.4 billion while also taking competitor Blueprint Medicines' shares down a few ticks in Tuesday's trading session.

Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) said ripretinib significantly improved progression-free survival (PFS) vs. placebo among fourth-line or later patients with gastrointestinal stromal tumors, meeting the primary endpoint of the Phase III INVICTUS study (6.3 months vs. 1 month; HR=0.15; p<0.0001). The company is planning an NDA submission in 1Q20...